Effect of mandibular advancement therapy on inflammatory biomarkers in obstructive sleep apnea: A systematic review.

National journal of maxillofacial surgery Pub Date : 2024-05-01 Epub Date: 2024-07-24 DOI:10.4103/njms.njms_79_22
Pooja Priyadarshini, Deepak Singh, Vipul Kumar Sharma, T P Chaturvedi, Akhilesh Kumar Singh
{"title":"Effect of mandibular advancement therapy on inflammatory biomarkers in obstructive sleep apnea: A systematic review.","authors":"Pooja Priyadarshini, Deepak Singh, Vipul Kumar Sharma, T P Chaturvedi, Akhilesh Kumar Singh","doi":"10.4103/njms.njms_79_22","DOIUrl":null,"url":null,"abstract":"<p><p>To review the literature on the effect of mandibular advancement therapy (MAT) on inflammatory biomarkers in obstructive sleep apnea (OSA). The present systematic review addresses the following focus question: What is the effect of MAT on inflammatory biomarkers in OSA? Electronic and manual literature searches were conducted on databases: PubMed/MEDLINE, Web of Science, and Cochrane Library for studies published until September 2021 to collect information about the effect of mandibular advancement therapy, a non-continuous positive airway pressure alternative measurement of OSA. A systematic literature review was performed following the PRISMA guidelines to identify studies evaluating the effect of MAT in patients suffering from OSA. Randomized clinical trials were included, and case reports, retrospective studies, literature reviews, <i>in-vitro</i> studies, observational studies, authors' opinions, letters to the editor, and engineering articles were excluded. Fifty-nine articles published before September 2021 were identified. Fifty-four articles met the inclusion criteria. After assessing inclusion criteria, three clinical trials were included with 148 patients suffering from OSA and treated with mandibular advancement therapy. The follow-up period ranged from two to three months, with the average follow-up being 1.66 months. The mean age of the patients was observed to be 53.11 ± 2.65 years. The mean Epworth Sleepiness Scale observed in patients in all three clinical trials was 9.75 ± 0.89. MAT in patients with moderate or severe OSA reduced apnea-hypopnea index but has less effect on inflammatory and metabolic biomarkers.</p>","PeriodicalId":101444,"journal":{"name":"National journal of maxillofacial surgery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371302/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"National journal of maxillofacial surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/njms.njms_79_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

To review the literature on the effect of mandibular advancement therapy (MAT) on inflammatory biomarkers in obstructive sleep apnea (OSA). The present systematic review addresses the following focus question: What is the effect of MAT on inflammatory biomarkers in OSA? Electronic and manual literature searches were conducted on databases: PubMed/MEDLINE, Web of Science, and Cochrane Library for studies published until September 2021 to collect information about the effect of mandibular advancement therapy, a non-continuous positive airway pressure alternative measurement of OSA. A systematic literature review was performed following the PRISMA guidelines to identify studies evaluating the effect of MAT in patients suffering from OSA. Randomized clinical trials were included, and case reports, retrospective studies, literature reviews, in-vitro studies, observational studies, authors' opinions, letters to the editor, and engineering articles were excluded. Fifty-nine articles published before September 2021 were identified. Fifty-four articles met the inclusion criteria. After assessing inclusion criteria, three clinical trials were included with 148 patients suffering from OSA and treated with mandibular advancement therapy. The follow-up period ranged from two to three months, with the average follow-up being 1.66 months. The mean age of the patients was observed to be 53.11 ± 2.65 years. The mean Epworth Sleepiness Scale observed in patients in all three clinical trials was 9.75 ± 0.89. MAT in patients with moderate or severe OSA reduced apnea-hypopnea index but has less effect on inflammatory and metabolic biomarkers.

下颌前突疗法对阻塞性睡眠呼吸暂停患者炎症生物标志物的影响:系统综述。
综述下颌前突疗法(MAT)对阻塞性睡眠呼吸暂停(OSA)患者炎症生物标志物影响的文献。本系统综述探讨以下重点问题:下颌前突疗法对阻塞性睡眠呼吸暂停(OSA)患者的炎症生物标志物有何影响?我们在以下数据库中进行了电子和人工文献检索:在 PubMed/MEDLINE、Web of Science 和 Cochrane Library 等数据库中检索了 2021 年 9 月之前发表的研究,以收集有关下颌前突疗法(一种非连续性气道正压替代测量 OSA 的方法)效果的信息。我们按照 PRISMA 指南进行了系统性文献综述,以确定评估下颌前突疗法对 OSA 患者影响的研究。随机临床试验被纳入其中,病例报告、回顾性研究、文献综述、体外研究、观察性研究、作者观点、致编辑的信和工程学文章被排除在外。共筛选出 59 篇 2021 年 9 月之前发表的文章。其中 54 篇符合纳入标准。在对纳入标准进行评估后,纳入了三项临床试验,共有 148 名 OSA 患者接受了下颌前突治疗。随访时间从2个月到3个月不等,平均随访时间为1.66个月。患者的平均年龄为(53.11 ± 2.65)岁。在所有三项临床试验中,患者的平均埃普沃思嗜睡量表(Epworth Sleepiness Scale)为(9.75 ± 0.89)。中度或重度 OSA 患者的 MAT 可降低呼吸暂停-低通气指数,但对炎症和代谢生物标志物的影响较小。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信